Emergent Transcriptomic Technologies and Their Role in the Discovery of Biomarkers of Liver Transplant Tolerance
- PMID: 26157438
- PMCID: PMC4476276
- DOI: 10.3389/fimmu.2015.00304
Emergent Transcriptomic Technologies and Their Role in the Discovery of Biomarkers of Liver Transplant Tolerance
Abstract
Liver transplantation offers a unique window into transplant immunology due, in part, to the considerable proportion of recipients who develop immunological tolerance to their allograft. Biomarkers are able to identify and predict such a state of tolerance, and thereby able to establish suitable candidates for the minimization of hazardous immunosuppressive therapies, are not only of great potential clinical benefit but might also shed light on the immunological mechanisms underlying tolerance and rejection. Here, we review the emergent transcriptomic technologies serving as drivers of biomarker discovery, we appraise efforts to identify a molecular signature of liver allograft tolerance, and we consider the implications of this work on the mechanistic understanding of immunological tolerance.
Keywords: biomarkers; gene; liver; tolerance; transcriptome; transplant; transplantomics.
Similar articles
-
Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization.Clin Biochem. 2016 Mar;49(4-5):404-10. doi: 10.1016/j.clinbiochem.2016.01.007. Epub 2016 Jan 13. Clin Biochem. 2016. PMID: 26794635 Review.
-
Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression.Am J Transplant. 2025 May;25(5):1045-1058. doi: 10.1016/j.ajt.2024.12.002. Epub 2024 Dec 18. Am J Transplant. 2025. PMID: 39706366 Clinical Trial.
-
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.J Hepatol. 2023 Jan;78(1):153-164. doi: 10.1016/j.jhep.2022.08.035. Epub 2022 Sep 7. J Hepatol. 2023. PMID: 36087863 Clinical Trial.
-
Marking a path to transplant tolerance.J Clin Invest. 2008 Aug;118(8):2684-6. doi: 10.1172/JCI36552. J Clin Invest. 2008. PMID: 18654643 Free PMC article.
-
A 'biomarker signature' for tolerance in transplantation.Nat Rev Nephrol. 2010 Oct;6(10):606-13. doi: 10.1038/nrneph.2010.112. Epub 2010 Aug 17. Nat Rev Nephrol. 2010. PMID: 20717098 Review.
Cited by
-
Modeling the Potential of Treg-Based Therapies for Transplant Rejection: Effect of Dose, Timing, and Accumulation Site.Transpl Int. 2022 Apr 11;35:10297. doi: 10.3389/ti.2022.10297. eCollection 2022. Transpl Int. 2022. PMID: 35479106 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources